Blood transfusion and spread of variant Creutzfeldt-Jakob Disease

Emerging Infectious Diseases

Volumn 13, Issue 1, 2007, Pages 89-96

  Dietz, Klaus ^a   Raddatz, Günter ^a   Wallis, Jonathan ^b   Müller, Norbert ^c   Zerr, Inga ^d   Duerr, Hans Peter ^a   Lefèvre, Hans ^e   Seifried, Erhard ^f   Löwer, Johannes ^g  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b FREEMAN HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e Blood Services of the German Red Cross West (DRK)   (Germany)

^f University of Ulm   (Germany)

^g PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CREUTZFELDT JAKOB DISEASE; DEATH; ENDEMIC DISEASE; FEMALE; HUMAN; MALE;

EID: 33846112170     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1301.060396     Document Type: Article

References (18)

1. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363:417-21.
2. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364:527-9.
3. Castilla J, Saa P, Soto C. Detection of prions in blood. Nat Med. 2005;11:982-5.
4. Wallis JP, Wells AW, Matthews JN, Chapman CE. Long-term survival after blood transfusion: a population based study in the North of England. Transfusion. 2004;44:1025-32.
5. Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science. 2001;294:1726-8.
6. Ghani AC, Donnelly CA, Ferguson NM, Anderson RM. Updated projections of future vCJD deaths in the UK. BMC Infect Dis. 2003;3:4.
7. Zerr I, Brandel JP, Masullo C, Wientjens D, de Silva R, Zeidler M, et al. European surveillance on Creutzfeldt-Jakob disease: a case-control study for medical risk factors. J Clin Epidemiol. 2000;53:747-54.
8. Bacchetti P. Unexamined assumptions in explorations of upper limit for cases of variant Creutzfeldt-Jakob disease. Lancet. 2001;357:3-4.
9. Bacchetti P. Age and variant Creutzfeldt-Jakob disease. Emerg Infect Dis. 2003;9:1611-2.
10. Bacchetti P. Uncertainty due to model choice in variant Creutzfeldt-Jakob disease projections. Stat Med. 2005;24:83-93.
11. Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet. 2004;363:51-61.
12. Clarke P, Ghani AC. Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility. J R Soc Interface. 2004;2:19-31.
13. Velasco-Hernandez JX. A model for Chagas disease involving transmission by vectors and blood transfusion. Theor Popul Biol. 1994;46:1-31.
14. Roberts MG, Heesterbeek JA. A new method for estimating the effort required to control an infectious disease. Proc R Soc Lond B Biol Sci. 2003;270:1359-64.
15. Huang XC, Villasana M. An extension of the Kermack-McKendrick model for AIDS epidemic. Journal of the Franklin Institute-Engineering and Applied Mathematics. 2005;342:341-51.
16. Inaba H, Sekine H. A mathematical model for Chagas disease with infection-age-dependent infectivity. Math Biosci. 2004;190:39-69.
17. Chadeau-Hyam M, Alperovitch A. Risk of variant Creutzfeldt-Jakob disease in France. Int J Epidemiol. 2005;34:46-52.
18. German Federal Ministry of Health Working Group. Overall blood supply strategy with regard to variant Cruetzfeldt-Jakob disease (vCJD). Transfusion Medicine and Hemotherapy. 2006;33(Suppl 2):1-39.